Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

ADC

This page shows the latest ADC news and features for those working in and with pharma, biotech and healthcare.

Takeda announces CHMP recommendation for Adcetris in Hodgkin lymphoma

Takeda announces CHMP recommendation for Adcetris in Hodgkin lymphoma

The ADC has been recommended with doxorubicin, vinblastine and dacarbazine. Takeda has announced that the European Medicines Agency’s human medicines committee has recommended Adcetris (brentuximab vedotin) as part of a ... The Committee for Medicinal

Latest news

More from news
Approximately 6 fully matching, plus 105 partially matching documents found.

Latest Intelligence

  • The rise of biologics: is the sector ready for future demand? The rise of biologics: is the sector ready for future demand?

    The global biologics industry is thus witnessing steady growth, as new modalities – including antibody-drug conjugates (ADCs), bispecific proteins, and cell and gene therapies – now account for a significant one-third

  • Putting the ovation into innovation: trends from ESMO Putting the ovation into innovation: trends from ESMO

    This really does represent the next generation of antibody-drug conjugates (ADCs) via its significant bystander effect, and with potentially new targets and payloads (for example HER3 in lung cancer) to

  • Surviving cancer: a new era for patients Surviving cancer: a new era for patients

    One such example is through the development of antibody-drug conjugates (ADC) – monoclonal antibodies attached to biologically active cytotoxic drugs. ... The FDA recently granted accelerated approval for the ADC trastuzumab-deruxtecan in patients with

  • Cortellis Drugs to Watch in 2020 report Cortellis Drugs to Watch in 2020 report

    10. Daiichi Sankyo and AstraZeneca’s Enhertu (trastuzumab deruxtecan) is also an ADC that targets HER2. ... Kadcyla, the only other anti-HER2 ADC in this market, is a direct competitor and differentiation versus this established drug will be key.

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The HER2-targeting antibody-drug conjugate (ADC) combines the HER2-targeting of Roche’s blockbuster breast cancer therapy Herceptin (trastuzumab) with a cell-killing chemotherapy component designed to improve its ability ... Roche already has a

More from intelligence
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest appointments

  • Glythera strengthens its scientific advisory board and appoints CSO Glythera strengthens its scientific advisory board and appoints CSO

    Dr Lutz was previously vice president of translation research and development at ImmunoGen, where he was responsible for all early-stage ADC development programmes. ... Dr Dave Simpson, chief executive officer of Glythera, said: “Robert Lutz’s

  • Glythera appoints Dr Mike Owen Glythera appoints Dr Mike Owen

    His experience in advancing scientific discoveries from the lab to commercialisation will be invaluable in helping us fully exploit our unique ADC platform, both in the development of our proprietary product

  • ADC Therapeutics expands team ADC Therapeutics expands team

    Appointments preceed its first antibody drug conjugate trials. ADC Therapeutics has significantly expanded its team head of putting its first antibody drug conjugates (ADCs) into clinical development. ... Michael Forer, CEO of ADC Therapeutics, said:

  • ImmunoGen hires VP product strategy ImmunoGen hires VP product strategy

    These programmes focus on antibody-drug conjugates (ADCs) to target cancers. The most successful of these ADCs so far is Kadcyla, which ImmunoGen developed with Genentech, now a part of Roche.

  • CytomX makes senior changes following Pfizer deal CytomX makes senior changes following Pfizer deal

    conjugates (ADCs) for cancer.

More from appointments
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • A MERGER THAT MATTERS

    Pegasus –the fifth largest healthcare agency in the UK –has merged with fellow Ashfield Health agencies Ashfield Digital and Creative (ADC) and Cambridge Biomarketing to form  Mind Matter, a ‘global creative

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To transform lives through communication that changes behaviour and improves health outcomes....

Latest intelligence

The importance of accelerating clinical trial diversity
Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
Digital Opinion Leaders: The Role of Influencers in Medical Communications
There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
Creating Hope Though Action – World Suicide Prevention Day
At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....

Quick links